Celera, an Applera Corp. business, earned a $2 million clinical milestone payment from Merck & Co. under the two companies cathepsin K inhibitor collaboration agreement. This payment recognizes Merck’s advancement of odanacatib (formerly MK-0822), an orally available highly selective inhibitor of the cathepsin K enzyme, into a Phase III trial as a potential treatment for osteoporosis. Should the candidate or others developed under the cathepsin K pact advance further, Celera will ...